Omega Benefit
$ 50.00
Size: 60 Softgels
Clinically Proven Omega-3 with 3× Greater Absorption and Superior Purity
Triple Absorption. Ultra-Small Softgel. Powerful Omega-3 Support for Heart, Brain, and Metabolic Health.
Omega Benefit® combines advanced science with exceptional purity in one of the smallest fish oil softgels available—just 0.3 inches long. Using patented MaxSimil® monoglyceride technology, this physician-formulated omega-3 achieves up to three times greater absorption than standard fish oils, delivering unmatched bioavailability and clinical effectiveness.*
Each softgel provides 650 mg of fish oil, including 300 mg of EPA and 130 mg of DHA—essential fatty acids that help maintain cardiovascular health, brain function, and balanced inflammation. The enteric-coated micro–softgel ensures gentle digestion and no fishy aftertaste, making it ideal even for those with sensitive stomachs, pancreatic, or gallbladder challenges.*
Every batch is third-party tested and IFOS five-star certified for purity, potency, and freshness—meeting the world’s highest standards for sustainable sourcing and safety.
Key Benefits
- Supports cardiovascular health and healthy lipid metabolism*
- Promotes mental clarity, focus, and emotional balance*
- Encourages healthy inflammation resolution and joint comfort*
- Aids glucose and insulin metabolism for balanced energy*
- Absorbs up to three times better than standard fish oils*
- Gentle on digestion with no fishy aftertaste*
- Features an ultra-small, easy-to-swallow 0.3-inch softgel*
- Third-party tested and IFOS five-star certified for purity and potency*
*These statements have not been evaluated by the FDA and are not intended to treat or cure any disease.
You’ll Enjoy Omega Benefit® if you…
- Prefer a small, easy-to-take softgel with no fishy aftertaste
- Want advanced omega-3 support that absorbs more efficiently
- Struggle with fatigue, low mood, or inflammation-related symptoms
- Have trouble swallowing large capsules or dislike fishy burps
- Value clinically tested supplements that meet the highest quality standards
- Prefer a clean, sustainably sourced, physician-formulated product
Our Patients Love Dr. Morrison’s Omega Benefit® Because…
- Fish-Gelatin Capsules
Many brands use beef gelatin capsules, which can be harder to digest and less suitable for those avoiding bovine products. Omega Benefit® uses fish-gelatin softgels, a cleaner, more compatible option for a truly marine-based supplement. - It delivers clinically proven triple absorption with MaxSimil® technology*
- Each softgel is incredibly small- just 0.3 inches long like a size of a jellybean, and easy to take daily
- It’s gentle on digestion and completely burp-free
- Every batch is IFOS five-star certified for purity, potency, and freshness
- It delivers real, noticeable improvements in energy, clarity, and overall wellness*
1 SOFTGEL PER SERVING
Fish Oil Concentrate | 650 mg
Total Omega-3 Fatty Acids | 430 mg
EPA (Eicosapentaenoic Acid) | 300 mg
DHA (Docosahexaenoic Acid) | 130 mg
DPA (Docosapentaenoic Acid) | 12 mg
Other Ingredients: Softgel (fish gelatin, vegetable glycerin, purified water), GRAS enteric coating (ethylcellulose, sodium alginate, purified water, medium-chain triglycerides, oleic acid, vegetable stearic acid, ammonium hydroxide), Mixed natural tocopherols (antioxidant)
DOES NOT CONTAIN: Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, GMOs, artificial colors, artificial sweeteners, or artificial preservatives.
Quality & Purity
- IFOS 5-Star Certified for potency, purity, and freshness
- Third-party tested for heavy metals and oxidation markers
- Sustainably sourced fish oil from cold-water Scandinavian species
- Enteric-coated softgel for optimal absorption and no aftertaste
Take 2 softgels daily, or as directed by your healthcare practitioner.
Caution: Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner.
The importance of the ratio of omega-6/omega-3 essential fatty acids
Several sources of information suggest that human beings evolved on a diet with a ratio of omega-6 to omega-3 essential fatty acids (EFA) of approximately 1 whereas in Western diets the ratio is 15/1-16.7/1. Western diets are deficient in omega-3 fatty acids, and have excessive amounts of omega-6 fatty acids compared with the diet on which human beings evolved and their genetic patterns were established. Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-6/omega-3 ratio, as is found in today's Western diets, promote the pathogenesis of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA (a low omega-6/omega-3 ratio) exert suppressive effects. In the secondary prevention of cardiovascular disease, a ratio of 4/1 was associated with a 70% decrease in total mortality. A ratio of 2.5/1 reduced rectal cell proliferation in patients with colorectal cancer, whereas a ratio of 4/1 with the same amount of omega-3 PUFA had no effect. The lower omega-6/omega-3 ratio in women with breast cancer was associated with decreased risk. A ratio of 2-3/1 suppressed inflammation in patients with rheumatoid arthritis, and a ratio of 5/1 had a beneficial effect on patients with asthma, whereas a ratio of 10/1 had adverse consequences. These studies indicate that the optimal ratio may vary with the disease under consideration. This is consistent with the fact that chronic diseases are multigenic and multifactorial. Therefore, it is quite possible that the therapeutic dose of omega-3 fatty acids will depend on the degree of severity of disease resulting from the genetic predisposition. A lower ratio of omega-6/omega-3 fatty acids is more desirable in reducing the risk of many of the chronic diseases of high prevalence in Western societies, as well as in the developing countries, that are being exported to the rest of the world.
Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis
Background: Fish oil supplementation has been shown to be associated with a lower risk of metabolic syndrome and benefit a wide range of chronic diseases, such as cardiovascular disease, type 2 diabetes and several types of cancers. However, the evidence of fish oil supplementation on glucose metabolism and insulin sensitivity is still controversial. This meta-analysis summarized the exist evidence of the relationship between fish oil supplementation and insulin sensitivity and aimed to evaluate whether fish oil supplementation could improve insulin sensitivity.
Methods: We searched the Cochrane Library, PubMed, Embase database for the relevant studies update to Dec 2016. Two researchers screened the literature independently by the selection and exclusion criteria. Studies were pooled using random effect models to estimate a pooled SMD and corresponding 95% CI. This meta-analysis was performed by Stata 13.1 software.
Results: A total of 17 studies with 672 participants were included in this meta-analysis study after screening from 498 published articles found after the initial search. In a pooled analysis, fish oil supplementation had no effects on insulin sensitivity compared with the placebo (SMD 0.17, 95%CI -0.15 to 0.48, p = 0.292). In subgroup analysis, fish oil supplementation could benefit insulin sensitivity among people who were experiencing at least one symptom of metabolic disorders (SMD 0.53, 95% CI 0.17 to 0.88, p < 0.001). Similarly, there were no significant differences between subgroups of methods of insulin sensitivity, doses of omega-3 polyunsaturated fatty acids (n-3 PUFA) of fish oil supplementation or duration of the intervention. The sensitivity analysis indicated that the results were robust.
Conclusions: Short-term fish oil supplementation is associated with increasing the insulin sensitivity among those people with metabolic disorders.